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Abstract
Observing fetal development in utero is vital to further the understanding of later-life
diseases. Magnetic resonance imaging (MRI) offers a tool for obtaining a wealth of information
about fetal growth, development, and programming not previously available using other
methods. This review provides an overview of MRI techniques used to investigate the metabolic
and cardiovascular consequences of the developmental origins of health and disease (DOHaD)
hypothesis. These methods add to the understanding of the developing fetus by examining fetal
growth and organ development, adipose tissue and body composition, fetal oximetry, placental
microstructure, diffusion, perfusion, flow, and metabolism. MRI assessment of fetal growth,
organ development, metabolism, and the amount of fetal adipose tissue could give early
indicators of abnormal fetal development. Noninvasive fetal oximetry can accurately measure
placental and fetal oxygenation, which improves current knowledge on placental function.
Additionally, measuring deficiencies in the placenta’s transport of nutrients and oxygen is
critical for optimizing treatment. Overall, the detailed structural and functional information
provided by MRI is valuable in guiding future investigations of DOHaD.

Introduction

© The Author(s), 2020. Published by Cambridge
University Press in association with the
International Society for Developmental
Origins of Health and Disease. This is an Open
Access article, distributed under the terms of
the Creative Commons AttributionNonCommercial-ShareAlike licence (http://
creativecommons.org/licenses/by-nc-sa/4.0/),
which permits non-commercial re-use,
distribution, and reproduction in any medium,
provided the same Creative Commons licence
is included and the original work is properly
cited. The written permission of Cambridge
University Press must be obtained for
commercial re-use.

The developmental origin of health and disease (DOHaD) hypothesis suggests that the environment a fetus experiences in utero can impact that individual’s health for the rest of their lives.1
Barker observed that fetuses born very small had increased risk of cardiovascular disease as
adults.2 Maternal conditions such as obesity and diabetes can also affect the fetus’s development,
thus increasing the risk for later-life disease.3,4 These examples demonstrate that individuals
who have experienced negative in utero programming through maternal, placental, or fetal
causes experience altered development that increases their risk for later-life health complications, many of which are metabolic in nature. Cardiovascular disease, obesity, and diabetes affect
increasingly large portions of our population. Understanding the early-life programming that
contributes to them may help reduce the burden of these health concerns for future generations.
In this review, we will focus on the role of in utero magnetic resonance imaging (MRI) in the
study of cardiovascular and metabolic consequences of the DOHaD relationship through fetal,
placental, and maternal metabolic perturbations.
MRI was developed in the 1970s and is used to visualize the internal anatomy and assess the
function of the human body.5 In the 1980s, MRI was used to visualize the pregnant anatomy,
offering a new modality to visualize the fetus and placenta.6 A precautionary approach to safety
limited the widespread adoption of MRI in pregnancy for many years. Current use of in utero
MRI follows guidelines such as those set out by the American College of Radiology.7 Recent
safety studies have not found an increase in adverse outcomes during pregnancy and early childhood after in utero exposure to MRI if contrast agents are not used.8–12 The major concerns
related to MRI in pregnancy include heating of the fetus and placenta, acoustic noise damage
to fetal and maternal hearing, and potential teratogenicity of magnetic fields. A more in-depth
look into these concerns is presented in other review papers.13,14
The use of in utero MRI is increasing in both research and clinical practice as it offers many
advantages over other imaging modalities.15 MRI does not use ionizing radiation and is noninvasive, making it safe/ideal to use in studying a vulnerable population.10 It is a modality with a
large field-of-view, allowing visualization of the entire uterus in an image volume.16 MRI provides excellent soft-tissue contrast and is multiparametric, enabling multiple contrast sources in
a single examination.17,18 Some of the MRI contrasts allow us to measure information about
function in addition to structure, permitting assessment of oxygenation, metabolism, and
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Table 1. Summary of different MRI techniques and their in utero application for studying the metabolic and cardiovascular consequences of DOHaD in humans
MRI technique

Placenta

Fetal
body

Brain

Heart

Liver

Kidney

Lung

Spleen

Structural MRI

x

x

x

x

x

x

x

x

Magnetization transfer

x

Fat-only or chemical-shift encoded (CSE) MRI

x

x

BOLD-fMRI

x

x

x

Relaxometry

x

x

x

Diffusion-weighted imaging (DWI) and diffusion tensor imaging
(DTI)

x

Intravoxel incoherent motion (IVIM)

x

Arterial spin labeling (ASL)

x

X

x

x
x

perfusion, to name a few. Fast 2D imaging, such as single-shot
spin-echo sequences, is routinely used to assess fetal and organ
growth and development, especially in the brain. Diffusion imaging is frequently used to investigate pathological placental invasion19,20 and has been used to measure lung maturity.21,22 For
more information on the basic MRI principles and essential topics
related to fetal MRI, please refer to the recent review paper by
Aertsen et al.23
In comparison, the use of positron-emission tomography (PET)
and x-ray computed tomography (CT) in pregnant humans is
uncommon due to the risks associated with ionizing radiation.24
Nuclear medicine, including PET, is only performed on pregnant
patients for diagnosis or therapy of life-threatening conditions.25
While CT remains an essential tool in diagnostics regardless of
pregnancy status, it is not commonly used in pregnancy research.26
Neither of these modalities are used in prospective pregnancy
research, as there is no clinical benefit to the patient to outweigh
the risk of the ionizing radiation delivered through imaging.
Ultrasound (US) is frequently used in pregnancy to assess structure
and limited functional parameters.27 Its relatively small field-ofview and typical 2D image presentation make visualization of
the entire fetus difficult late in gestation.28 US is also relatively
insensitive to metabolism and oxygenation.
MRI does have limitations such as accessibility29 and cost.30
These barriers include health centers without access to advanced
MRI techniques29 or expertise to use them in utero.
Furthermore, MRI is a relatively slow imaging technique and is
therefore sensitive to maternal and fetal motion, the latter of which
is random and unpredictable.31 When investigating a developing
fetus’s small anatomy, partial volumes32,33 and spatial resolution34
can be limiting. Additionally, the physical configuration of the
MRI system can limit the size of the patient that can be imaged,
particularly in the late second and third trimesters. The increasing
availability of larger bore MRI systems (70 cm bore) is alleviating
this issue. Despite these limitations, in utero MRI provides us with
a wealth of knowledge about fetal growth, development, and programming not previously available.
This review will describe different MRI techniques used to study
the cardiovascular and metabolic consequences of DOHaD
(Table 1). We will discuss the investigation of fetal growth and
organ development, body composition and adipose tissue,
oxygenation and oximetry, placental microstructure, diffusion,
perfusion and flow, and metabolism using in utero MRI.
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x

x

Phase-contrast (PC) MRI
Magnetic resonance spectroscopy (MRS)

Blood

x

X

Assessment of fetal growth and organ development
Fetal growth assessment is regularly used to identify fetuses
growing insufficiently (fetal growth restriction, FGR) or excessively
(macrosomia), both of which are associated with the later-life
metabolic consequences of DOHaD. MRI can monitor fetal growth
through volumetric measurements, which have been shown to be
superior to US estimated fetal weight.35,36 The excellent soft-tissue
contrast provided by MRI also allows for the measurement of
organ growth, including liver, kidneys, brain, lungs, heart, and
placenta.37 The assessment of differential organ growth is useful
for identifying altered growth distributions such as asymmetric
FGR. MRI sequence parameters are chosen to optimize the images
for an organ or region of interest, and in some cases, specialized
acquisitions and reconstructions are required. Most notably, the
fetal heart requires dedicated MRI sequences due to the motion
through the cardiac cycle. Recent fetal cardiac MRI techniques
are discussed in a review by Macgowan et al.38 These techniques
could be applied to study cardiac remodeling in response to an
adverse in utero environment as they offer excellent structural
views of the fetal heart through the entire cardiac cycle. While
the use of MRI for fetal organ assessment has been focused on
understanding normal development or assessing congenital malformations, the knowledge gained will help future studies on the
cardiovascular and metabolic consequences of the DOHaD
hypothesis.

Adipose tissue and body composition
The earliest reports of MR images in pregnancy include a description of visible fetal adipose tissue.6,39 Today, the ability to image
adipose tissue, including that of the fetus, has far surpassed these
early descriptions. As a result, a review of current techniques to
image adipose tissue shows how refined and varied these newer
tools have become.40,41
Fetal adipose tissue can be used to assess developmental programming’s effects because it reflects the fetus’s energy deposition
through pregnancy.42 For instance, fetuses of mothers with diabetes have an increased risk of being born with macrosomia, often
due to an increase in offspring adipose tissue.43 Changes in adipose
tissue may be an early indicator of an altered fetal metabolism that
could result in the development of metabolic syndrome later in life.
Through fetal MRI, Anblagan et al. observed that fetuses of
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Fig. 1. (A) A single slice of 3D CSE-MRI image of third-trimester pregnancy. Bright pixels represent areas with high lipid
content, and dark pixels represent areas of low lipid content.
The segmentation of fetal adipose tissue is shown in yellow.
(B) 3D rendering of segmented fetal adipose tissue. Image
courtesy of the Pregnancy Research Group.

mothers with pre-existing diabetes had a greater adipose tissue volume than controls.44 Using fat-only images at 34 weeks gestation,
they found the total adipose tissue volume was increased and identified intra-abdominal adipose tissue more often in the fetuses of
diabetic mothers.44 Furthermore, using fat-only MR images,
Berger-Kulemann et al. found that the fetuses of mothers with
well-controlled diabetes did not have thicker subcutaneous adipose
tissue than controls and attributed this to the strict control of the
maternal glucose metabolism.45 This finding suggests that careful
control of the mother’s metabolism may minimize the effects of
metabolic diseases such as diabetes on the fetus’s prenatal
programming.
MRI is also capable of measuring the amount of lipid within a
tissue using a method known as chemical shift encoded (CSE) MRI
(see Fig. 1 for example images). CSE-MRI exploits the different resonant frequencies of lipids and water to create quantitative images
of lipid or water content of tissues.46 Giza et al. have used CSE-MRI
in the fetus to show that fetal adipose tissue has an increasing proportion of lipid as the pregnancy progresses.47 Furthermore, this
technique has been applied to study a maternal high-fat diet’s
effect on fetal adipose tissue development in guinea pigs.48
Sinclair et al. found that mothers exposed to a lifelong high-fat diet
produced fetuses with increased lipid deposited in the adipose tissue and liver compared to those on a control diet.48 These examples
provide evidence that maternal metabolism can influence fetal
metabolism to the extent that alterations in fetal adipose tissue
development and lipid deposition are detectable with MRI, which
may give early insight into the programming of the metabolic consequences of DOHaD.
Fetal motion is a significant obstacle for fetal MRI, including
MRI of fetal adipose tissue. In the future, application of motionresistant techniques, such as radial CSE-MRI,49 to image the fetus
should mitigate the problem of motion. CSE-MRI can also assess
fatty acid saturation to determine the proportions of saturated,
mono-unsaturated, and poly-unsaturated fatty acids in tissue.50
This technique could give more insight into both maternal and
fetal lipid metabolism.
After measuring fetal adipose tissue volume, fetal body composition can be determined by combining the adipose tissue measure
with total fetal volume. Anblagan et al. used this idea to create a
formula for estimating fetal weight using the different densities
for fat mass and fat-free mass.44 This technique could be extended
to include a bone measurement using any MRI technique specialized for imaging bone51 to determine the three main body composition compartments: bone mass, fat mass, and fat-free mass.
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When applied to the fetus, this may allow researchers to study
the effects of metabolism changes on any compartments of the
developing body composition.

Fetal and placental oximetry
One of the placenta’s many functions is to provide the fetus with an
adequate supply of oxygen.52 However, if the placenta is impaired
and unable to provide the fetus with adequate oxygen, the fetus
is at risk for severe health conditions such as FGR.53,54 Although
techniques exist to assess the placenta’s oxygen exchange, they
are either invasive55 or based on indirect measurements.56–58
Fortunately, MRI provides noninvasive techniques that can be used
to accurately measure changes in fetal and placental oxygenation.
MRI is sensitive to blood-oxygen content because of the difference in magnetic susceptibility between oxygenated and deoxygenated hemoglobin.59 Two techniques that utilize this difference in
magnetic properties are blood-oxygen-level-dependent (BOLD)
MRI and vascular relaxometry.
BOLD imaging, often used in the brain, is the MR contrast mechanism used in functional MRI (fMRI) to visualize blood oxygenation
changes related to neuronal activation.60 Deoxyhemoglobin results in
a decrease in the BOLD-fMRI signal, while oxyhemoglobin results in
an increase,61 allowing one to visualize the oxygen saturation change.
Numerous publications have focused on the use of BOLD-fMRI
for assessing oxygenation in the placenta and other fetal organs in
both animals and humans. It has been used to assess oxygen saturation change in the placenta and fetal organs in lambs under
maternal hypoxia.62–64 Sorensen et al. further investigated fetal
liver oxygenation change in lambs, finding an oxygen saturation
change in response to maternal hypoxia to be more pronounced
in the right side of the fetal liver, which could be due to increased
venosus shunting.65 Interestingly, unlike the placenta and other
fetal organs, the fetal brain did not experience a change in the
BOLD-fMRI signal when placed under hypoxic, normoxic, or
hyperoxic conditions in fetal lambs.66 This finding suggests a brain
sparing mechanism67–69 that was also observed in fetal mice.70 In
contrast, Wedegärtner et al. found a decrease in the BOLD-fMRI
signal in fetal lamb brain, heart, and liver during maternal hypoxia,
though the decrease in signal was significantly smaller in the brain
compared to the other two organs.71 BOLD-fMRI was also used to
show a difference in response to maternal hyperoxygenation in
growth-restricted fetal rats as they experienced a smaller increase
in fetal tissue oxygenation compared to control fetal rats.72
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In human studies, BOLD-fMRI has been used to investigate placental and fetal oxygenation primarily during maternal hyperoxia,
a treatment implemented for increasing fetal oxygenation by providing oxygen to the mother.73,74 During maternal hyperoxia, the
oxygenation of the placenta and the fetal liver, fetal spleen, and fetal
kidney was found to increase.75,76 The brain sparing mechanism
observed in fetal rats70 has also been seen in humans as fetal brain
oxygenation was not found to increase in response to maternal
hyperoxia, in contrast to other fetal tissues.76,77 Luo et al. further
explored the utility of the BOLD-fMRI signal using placental
time-to-plateau maps to assess placental oxygen transport in
monozygotic twin pairs to encapsulate regional variations in placental function. This study found that in growth-restricted twins,
the smaller twin needed more time to reach a hyperoxic steady
state.78 In summary, BOLD-fMRI has been used to successfully
assess placental and tissue oximetry changes, which could provide
information regarding the consequences of placental dysfunction
in DOHaD.
BOLD-fMRI only provides relative oxygenation values rather
than a quantitative value or quantitative change for blood volume
or oxygen saturation.99 Despite these limitations, it has the potential to be useful in many clinical applications. The next step for
BOLD-fMRI would be assessing fetal response to maternal
hyperoxia in cases of severely impaired placental function to better
identify fetal nonresponsiveness, which is a predictor of adverse
neonatal outcome.76
Vascular relaxometry is the measurement of the MR relaxation
times (T1, T2, and T2*) of blood.79 Due to the difference in
deoxyhemoglobin and oxyhemoglobin’s magnetic properties, the
relaxation parameters of blood are sensitive to oxygen content.61
By quantifying these relaxation times, fetal vascular properties,
such as blood hematocrit and oxygen saturation, can be determined.80–83 T1 and T2 relaxation times of fetal blood have been
quantified as a function of blood hematocrit and oxygen saturation
at 3.0 Tesla.84 Human umbilical cord blood’s relaxation times have
also been quantified85 and used to create models that estimate
blood hematocrit and oxygen saturation.86 Zhu et al. found the
umbilical vein’s T2 relaxation time to be a useful marker for assessing response to hypoxia in growth-restricted fetuses.87 Another
methodology that has been successful in assessing blood oxygenation is susceptibility-weighted imaging. The referenced studies
have successfully used the principles of MRI susceptometry to
evaluate fetal cerebral venous blood oxygenation saturation.88,89
Furthermore, Yadav et al. showed a decrease in cerebral blood oxygenation with increasing gestation in second- and third-trimester
fetuses,90 most likely due to the marginal decrease in the umbilical
venosus blood oxygenation and increased metabolic demands of
the fetus during the investigated gestational period.91,92
Tissue relaxometry has also been investigated, particularly in
the placenta.93–96 In the case of placental dysfunction, T1, T2,
and T2* were found to be lower than in gestational age (GA)
matched normal placentae.93,94,96–99 The decrease in these relaxation times is most likely due to changes in tissue oxygenation and
morphology. These changes can be the result of the presence of
problems like infarction or necrosis. Placental T1 has also been
investigated in cases of maternal hyperoxia. In both normal and
dysfunctional placentae, the hyperoxic T1 increased, representing
an increase of PO2 in blood and tissue.99–101 Furthermore, fetal liver
T2* relaxation times were found to increase following maternal
oxygenation.102 Both vascular and placental relaxometry are sensitive to fetal oxygen change and can be used to assess oxygenation in
cases of DOHaD.
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Limitations with vascular relaxometry concern the biophysical
models used to determine blood hematocrit and oxygen saturation.
These limitations include the magnetic susceptibility differences
between adult and fetal hemoglobin,88 physiological variations
between participants,85 and bias from methemoglobin, which
can decrease relaxation times.86 Despite these limitations, vascular
relaxometry can be useful in many clinical applications, and the
next step can potentially be used to optimize the delivery timing
of late-onset growth-restricted fetuses.87
Placental microstructure
In addition to oxygenation, the microstructure of the placenta can
be assessed using relaxometry. A negative correlation exists
between placental T1 and GA, placental T2 and GA, and placental
T2* and GA in normal placentae.93–96 It has been speculated that
the change in relaxation times is due to changes in morphology and
function instead of changes in blood volume. Magnetization transfer ratio (MTR), which is the ratio of bound protons to total protons in tissue, is another quantitative measure used to investigate
placental morphology. MTR reflects the non-vascular component
of the placental volume relative to total placental volume. Ong et al.
did not find placental MTR to vary significantly between GA
groups or between normal pregnancies and those affected by
FGR and pre-eclampsia.103 These findings suggest that total placental volumes are maintained regardless of GA and the presence
of FGR or pre-eclampsia. In short, both relaxometry and MTR can
provide additional insight into placental composition, which could
reflect placental adaptations to the in utero environment at a
macromolecular level.
Diffusion, perfusion, and flow
It can be challenging to identify a growth-restricted fetus in utero.
There are still many cases of FGR that are left undiagnosed because
current clinical methods for identification, such as umbilical artery
Doppler ultrasound, fail to identify these fetuses, especially in
obese women.104 The ability to reliably and consistently identify
FGR fetuses is critical for monitoring and early intervention.105
Since the placenta provides nutrients and oxygen to the developing
fetus via the maternal blood supply, any reduction in the placenta’s
blood flow and perfusion may result in FGR.106,107 To improve
clinical diagnostic capabilities for FGR and better understand
placental function, several studies have used specialized MRI
techniques to investigate normal and abnormal perfusion across
placental compartments and assess microstructure and microvasculature. These techniques include diffusion-weighted imaging
(DWI), diffusion tensor imaging (DTI), intravoxel incoherent
motion (IVIM), arterial spin-labeling (ASL), and phase-contrast
MRI (PC-MRI).
DWI and DTI are diffusion-based techniques that characterize
water molecules’ movement within tissues to investigate placental
microstructure (see Fig. 2 for example images). DWI is sensitive to
differences in the magnitude of water molecule diffusion (s/mm2),
while DTI also accounts for the direction of water molecule
diffusion.108 Slator et al. assessed diffusion in the healthy placenta
and found differences across placental compartments, indicating
distinct microvascular and tissue microstructure in the maternal
and fetal sides of the placenta.109 Diffusion MRI has been used
to quantify the putative functional placental tissue (PFPT) volume,
which is determined by high diffusion-weighted signal intensity in
the placenta.105 Diffusion parameters (diffusivity and fractional
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Fig. 2. Example of diffusion-weighted images of third-trimester pregnancy with different diffusion weightings [(A) b = 0 s/mm2, (B) b = 35 s/mm2, and (C) b = 750 s/mm2]. It is
possible to estimate diffusion and perfusion in tissues by performing a bi-exponential fit of MRI data with different diffusion weightings. Figure courtesy of C. Rockel and the
Pregnancy Research Group.

anisotropy) are reduced in the PFPT of placental FGR compared to
healthy controls, suggesting the development of the villous
network is affected in placental FGR.105 The volume of PFPT
decreases significantly in placental FGR compared to healthy
controls, while brain volume measured from diffusion images
remains similar, indicating a brain sparing effect.110 DWI and
DTI may provide insight into placental villous development
changes in examples of negative fetal programming, such as FGR.
While IVIM is a type of DWI, it differs in technique as IVIM
utilizes additional parameters (perfusion fraction, pseudodiffusion related to blood microcirculation) to characterize water
molecule movement within each image voxel to provide a measure
of perfusion and diffusion.111 IVIM has poor sensitivity in low
blood volume areas but performs well in high blood volume
regions such as the placenta. It was shown to be a reproducible
technique for measuring placental and fetal lung and liver perfusion, perfusion fraction, and diffusion.112 Perfusion fraction measurements were less reliable, particularly in the kidneys and brain,
due to small organ size and fetal motion.112 It should be noted that
the choice of MRI field strength (1.5 vs. 3.0 Tesla) affected the measured perfusion fraction of liver and lung, with higher perfusion
fractions being measured at 3.0 Telsa.112 These results highlight
that IVIM is a difficult imaging technique to perform, particularly
in the moving fetus’s small organs. Despite these limitations, IVIM
has been used to measure decreased perfusion fraction across the
placenta in small for gestational age (SGA) compared to healthy
controls in the second trimester.113 IVIM measures of perfusion
in healthy placentae showed a higher perfusion fraction in the
outer (maternal) zone than the inner (fetal) zone.114 The difference
in perfusion is reduced in FGR compared to control pregnancies, as
there is a reduction of placental perfusion fraction in the outer zone
and slightly elevated perfusion fraction in the inner zone.114
It should be noted that these studies were performed at single sites
with relatively small numbers of patients, so larger multicenter
studies are needed to confirm the utility of IVIM for fetoplacental
assessment.
ASL magnetically labels the water molecules found in arterial
blood to create an endogenous contrast agent to quantify perfusion
(ml/min/g).111 ASL has been used to investigate placental perfusion
in healthy placentae of animals106 and humans.113,115–117 It has
shown spatial heterogeneity in perfusion, which may be related
to the cotyledons of the placenta.106,115–117 Hutter et al. used
ASL in combination with T2* measurements to quantify placental
perfusion and oxygenation in the healthy placenta.116 ASL has also
been used to identify SGA fetuses in the second trimester by measuring lower placental perfusion in SGA fetuses compared to
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healthy controls.113 Assessment of perfusion through IVIM or
ASL in the placenta provides researchers and clinicians additional
methods to probe placental function and adaptations.
PC-MRI is a technique used to measure flow on a larger scale
than the perfusion measured by IVIM or ASL. PC-MRI is used to
measure blood flow velocity (cm/s) as a function of time in either
individual slices118 or over a 3D volume.119 From these data, it is
possible to quantify the time-varying blood flow (ml/s) through
vessels. PC-MRI has been used to determine ranges of blood flow
through major fetal vessels in healthy pregnancies.118 3D PC-MRI
(also known as 4D Flow) has been performed in pregnant large animal models to measure in- and out-flow of the uterus, umbilical
cord, and fetal heart120 and measure flow through major fetal vessels including the ductus venosus and ductus arteriosus.121 Flow
through the uterine arteries was also measured in human pregnancies, with velocity measurements agreeing with those obtained with
Doppler US.122 A strength of PC-MRI is the ability to assess blood
flow in a 3D volume, which could allow assessment of placental
and cardiovascular adaptations throughout gestation as a result
of fetal programming.
A common limitation of diffusion and perfusion MRI is the lack
of consensus in the choice of models used to fit placental diffusion
data; however, Slator et al. have proposed an anisotropic IVIM
model that explains human placental diffusion data better than
the apparent diffusion coefficient, IVIM and DTI models.109
There are a lack of data validating the diffusion and perfusion
results against accepted clinical techniques, and some diffusion
analysis methods can be adversely affected by placental location
within the uterus.105,109 The blood vessels that can be assessed with
PC-MRI are limited by spatial resolution, making it difficult to perform in small animal models. In the future, studies may focus on
developing techniques for clinical use, assessing placental microstructure in normal and abnormal placentae, and assessing of placental perfusion dynamics. Such developments would help
understand placental adaptations to different DOHaD-related
conditions such as maternal obesity, diabetes, and altered fetal
growth.
Metabolic MRI
Optimal fetoplacental metabolism is essential for the fetus’s development in utero, and metabolic dysfunction is a possible cause of
FGR.123 In this section, we focus on the metabolic implications of
FGR, which are relevant to DOHaD as growth restriction is known
to impact health status later in life. A large focus of metabolic imaging is brain development; therefore, many of the spectroscopy
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studies mentioned here investigate the developing brain’s metabolic conditions in utero. MR techniques can provide direct measurements of metabolism in vivo and may be used to identify
biomarkers useful to detect differences between normal and abnormal fetoplacental metabolism quantitatively.124
Magnetic resonance spectroscopy (MRS) provides data on
metabolites in vivo, allowing for noninvasive measurements
related to fetal or placental tissue’s metabolic status. MRS measures
the signal from hydrogen (1H) nuclei or other MR-sensitive nuclei,
such as 31-phosphorus (31P). MRS is used to distinguish distinct
molecules in a volume of interest based on their resonant frequencies and can be used to quantify the concentration of a metabolite
by measuring the area under its spectral peak.124 Successful fetoplacental MRS experiments have been demonstrated using clinical
MRI scanners at field strengths of 1.5 and 3.0 Tesla.
The first study to demonstrate 1H-MRS of the human placenta
in vivo was published in 2012 by Denison et al., specifically looking
at choline, which is associated with a normal cell turnover rate in
the developing fetal brain.125 The study found a 60-fold reduction
in the choline/lipid ratio in FGR fetuses’ placentas, indicating
placental failure and possible fetal hypoxia.125 Glutamate and
glutamine (Glx) are related to the production of nucleotides and
amino sugars needed for cell proliferation and have also been studied via MRS in the human placenta. Macnaught et al. reported that
FGR placentae were found to have a significantly lower Glx/choline
ratio than healthy controls at the same GA,126 demonstrating the
prospect of Glx as a biomarker of placental function. 31P-MRS has
more recently been employed to study placental metabolism, with
studies focusing on phosphodiester (PDE) and phosphomonoester
(PME) metabolites important for cell membrane degradation and
formation, respectively. This technique has been used to demonstrate an elevated PDE/PME ratio in the placenta for pregnancies
with early-onset pre-eclampsia compared to healthy pregnancies,127 as well as a case of abnormally high PDE signal from the
placenta of a recently deceased fetus.128
1
H-MRS has more commonly been used to study fetal brain
metabolism, specifically targeting metabolites such as N-acetylaspartate (NAA), which is involved in neuronal metabolism, and lactate, which is related to hypoxia as a possible result of placental
insufficiency.129 Various 1H-MRS fetal brain studies have reported
differences between healthy and FGR fetuses, including elevated
lactate found in brains of FGR fetuses127,129,130 and reduced
NAA/choline and NAA/creatine ratios in FGR fetuses.131–133
Sanz-Cortes et al. included SGA fetuses in the study. They found
that some SGA fetuses demonstrated reduced NAA/choline ratios
similar to the FGR fetuses,132 indicating that MRS may introduce a
method of differentiating between metabolically healthy small
fetuses and growth-restricted fetuses.
When studying complex systems like the fetus and placenta, it is
useful to have spatial information to discern different metabolites’
locations. Although non-proton MRI is useful for measuring
different metabolites, it is challenging to perform due to low
endogenous signal compared to 1H. With the advancement of
hyperpolarized (HP) MRI, it is possible to image non-proton molecules in a reasonable time frame by boosting the nuclear magnetic
signal up to 10,000-fold.134
In vivo hyperpolarized MRI of the fetus or placenta is a very new
field, and as such, there are only three animal studies in the literature to discuss. Friesen-Waldner et al. validated the technique of
imaging injected hyperpolarized [1-13C]pyruvate and its downstream metabolites (lactate, alanine, and bicarbonate) in utero
using 3D chemical shift imaging on a pregnant guinea pig model

https://doi.org/10.1017/S2040174420001154 Published online by Cambridge University Press

S. A. Giza et al.

Fig. 3. Typical hyperpolarized 13C metabolite images overlaid on coronal T2 of the
same guinea pig at 22.5 s post-injection of [1-13C]pyruvate solution. Images of signal
from two metabolites are shown here: pyruvate is shown in magenta (A) and lactate in
cyan (B). The placentae are outlined in each image Image courtesy of L. Smith, L.
Friesen-Waldner, and T. Regnault.

(Fig. 3). This study reported pyruvate and lactate signal from all 30
healthy placentas and fetal livers.135 A proof-of-concept paper by
Markovic et al. focused on the use of the chinchilla as a model
animal for fetoplacental research and used HP 13C MRI to observe
lactate and pyruvate in the placentae of four healthy pregnancies.136 Lastly, Wang et al. investigated placental metabolism via
HP 13C MRI in a Wistar rat model of pre-eclampsia and observed
differences in urea kinetics and pyruvate to lactate metabolism in
the placentae of pre-eclamptic pregnancies compared to healthy
pregnancies.137 This study imaged three injected hyperpolarized
substrates – [1-13C]pyruvate, 13C-bicarbonate, and 13C-urea –
and reported observing urea, bicarbonate, pyruvate, lactate, and
alanine in placentae, and urea in some fetal livers. It is important
to note that HP 13C MRI has been performed successfully in
non-pregnant human subjects in vivo.137 The validation of this
technique in human patients combined with the success of fetoplacental imaging in multiple animal models suggests the obvious
next step in this field is the translation to HP 13C MRI studies
of human pregnancy.
Both MRS and hyperpolarized MRI have challenges associated
with them. An obvious challenge is fetoplacental motion, which
may lead to MRS signal detection outside of intended voxels
and artifacts in HP MRI images. Another challenge is the need
for specific hardware, such as specialized RF coils for non-proton
MRS and MRI. Limitations specific to MRS include long scan times
that are not clinically translatable, difficulty performing small animal studies due to the low sensitivity resulting from the small fetus/
placenta size, and limited spatial coverage. HP 13C MRI limitations
include the need for specialized equipment to hyperpolarize
samples, limited resolution, and rapid signal decay that limits
the temporal window for imaging post-injection.
Conclusions
While we understand that the environment a fetus experiences
in utero can alter its later-life health through developmental programming, the mechanisms supporting the DOHaD hypothesis
remain unclear. Imaging may help answer some of the questions
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regarding when and how this programming takes place. MRI is
ideal for this task thanks to its ability to image different structures
and function noninvasively during pregnancy.
Examining fetal growth and organ development allows for
identifying under- or over-growth and deviations from normal
organ development that may result from an adverse in utero environment. The ability to assess structural changes in adipose tissue
and body composition can help determine if and when in gestation
the programming is taking place, through alterations in lipid deposition resulting from altered nutrient availability. Measurement of
placental and fetal oxygenation using MRI can provide insight into
the placental tissue function and any fetal adaptations that compensate for deficiencies. Furthermore, MRI methods that assess
diffusion and perfusion can provide additional insight into placental tissue structure and function. Finally, the ability to probe specific metabolites will help us understand the normal metabolic
function of the fetus and placenta in utero. The information from
the metabolites will also provide information about how the fetus
and placenta can be altered in disease on a chemical level, making it
one of the most powerful tools MRI has to offer the field
of DOHaD.
This review of MRI used to study DOHaD has revealed a focus
on FGR. However, we believe that MRI can help investigate other
DOHaD-related metabolic or cardiovascular conditions, such as
macrosomia, pre-eclampsia, maternal diabetes, and maternal
obesity. It could also be a means of monitoring interventions aimed
at reducing undesirable fetal programming throughout gestation.
Overall, MRI is a useful and diverse research tool for investigating the cardiovascular and metabolic consequences of DOHaD
thanks to its excellent soft-tissue contrast and ability to quantify
function in the fetus and placenta. The information it provides will
help bridge the gap from the cellular mechanisms of programming
to the clinical prevention of later-life disease.
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